ZEISS MyoCare lenses
A better outlook on life.
Our most effective lens designs aimed at slowing the progression of myopia. MyoCare is backed by ZEISS innovation and more than a decade of experience in developing lenses to manage the progression of myopia.
The two designs in the ZEISS MyoCare portfolio include
Myopia is a growing concern worldwide
One problem—many solutions.
Optical, medical, and behavioral treatments.
Because of its multifactorial causes, there’s no one-and-only treatment for myopia. In fact, there are many treatment options on the market including optical, medical, and behavioral treatments.
The choice of myopia treatments for children should be based on the age of onset, and axial length or refraction at a given age, as well as knowledge of their individual rate of progression and overall risk profile. Comprehensive myopia treatments include a combination of lifestyle advice, a refractive correction method for full-time use, and myopia control methods to reduce or eliminate further progression.
A new lens design.
Creating simultaneous competing defocus.
Our latest lens designed to manage progressive myopia in children is built on more than a decade of ZEISS innovation and experience in myopia management, in collaboration with optical experts including material and vision scientists, eye care practitioners, and academics. The design of ZEISS MyoCare lenses incorporates scientific concepts from proven scientific research, evidence-based learnings, and effective treatments, including orthokeratology, soft multifocal contact lenses, science, and the new generation of eyeglasses.
Finding the right balance.
The perfect combination of distinct optimization parameters and a specific design.
An effective myopia mangement lens must overcome certain design challenges and strike an optimum balance between myopia progression management and good vision. To achieve this, we have included the following in our ZEISS Myopia Management solutions:
- A central zone small enough to establish an effective functional zone projecting myopic defocus on the near periphery close to the fovea
- A mean addition surface power to induce the intended relative myopic defocus
- A carefully selected fill factor to deliver high efficacy while preserving good wearability
ZEISS ClearFocus design.
Addressing the constant movement of the eyes.
Eyeglass lenses have to take into account the moving eye behind the lens to ensure that the intended correction and myopic defocus are maintained for all gaze angles. With the ZEISS ClearFocus design, both the optimal refractive correction according to the patient’s refractive requirements and the intended myopic defocus are maintained for all gaze directions. This is important not only for distinct viewing behavior through the central clear zone when pursuing a focused task, but also for unintended gazes and saccades to the lens periphery.
Additionally, the ZEISS ClearFocus design effectively minimizes the induction of hyperopic defocus as opposed to typical spherical single vision lenses.
A new approach to measure effectiveness.
Emmetropic progression ratio.
Each myopia progression management intervention has its own advantages and disadvantages, however each option pursues a common target: to slow the progression of myopia.
Developmental milestones offer important insights into a child's developmental health. Reaching specific milestones at a given age shows a child is developing as expected. A comparison between normal physiological growth and the patient’s current growth is needed to observe whether there is some type of non-physiological deviation present.
The ZEISS MyoCare shows an average emmetropic progression ratio for axial length with an average of 70% and ZEISS MyoCare S with an average of 68%. 4
Myopia management lens solutions, because every child is unique.
ZEISS MyoCare and ZEISS MyoCare S
When it comes to ensuring treatment success, compliance is key. That's why it's crucial for eye care providers to choose a strategy that emphasizes high wearability and comfort. By selecting an approach that patients will find easy and comfortable to use, you can help to ensure optimal results and patient satisfaction:
- MyoCare®, a hard-design variant with a smaller clear zone and stronger mean addition power that is suitable for younger children, for example, where progression is more rapid.
- MyoCare® S has a larger central clear zone with a softer mean addition power that is more suitable for older children and adolescents, for example, where progression is slower and there is a need for easier adaptation.
Why you should choose MyoCare® lenses.
Vision as good as with single-vision lenses.
MyoCare® portfolio
A better outlook on life.
-
1
Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S, Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050, Ophthalmology. 2016;123(5):1036–1042.
-
2
Chen M, Wu A, Zhang L, et al. The increasing prevalence of myopia and high myopia among high school students in Fenghua city, eastern China: a 15-year population-based survey. BMC Ophthalmol. 2018;18(1):159. doi: 10.1186/s12886-018-0829-8.
-
3
Xiong S, Sankaridurg P, Naduvilath T, Zang J, Zou H, Zhu J, Lv M, He X, Xu X. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol. 2017; 9 5 ( 6 ):551- 5 6 6 . d o i: 10 .1111/ a o s .13 4 0 3.
-
4
Ohlendorf, A., et al. (2024, May 5-9). Myopia control efficacy through Emmetropic Progression Ratio:1-year of lens wear with cylindrical annular refractive elements (CARE)
[Conference presentation abstract]. The Association for Research in Vision and OpthalmologyOphthalmology (ARVO) Annual Meeting, Seattle, WA, United States.
EPR for ages 7 to 12-year-old children as sample size for ages 6 and 13 was small. When the entire sample of 6 to 13-year-olds were considered, EPR for ZEISS MyoCare was 71%.
-
5
Two-year prospective, multi-center, double-blind, randomized controlled clinical trial lead by Tianjin Eye Hospital Optometric Center, China, 2022, on 80 myopic children wearing ZEISS MyoCare Rx lenses, 80 myopic children wearing ZEISS MyoCare S Rx lenses and80 Myopic children wearing ZEISS Single Vision lenses. 12-month interim results presented at ARVO 2024.
-
6
Hong Kong Polytechnic University owns granted patents (including Chinese patent: CN103097940) on annular concentric lens for myopia control, which are licensed to Carl Zeiss. In 2021, in collaboration with Wenzhou Medical University, Carl Zeiss began to develop the latest cylindrical annular refractive elements technology for eyeglass lenses used in MyoCare lens designs.
-
7
We can however say something like exaggerated animation, not real image. The rings can be seen with the naked eye if the lens is held at a certain angle.